Patents by Inventor Tesshi Yamada
Tesshi Yamada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11733250Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.Type: GrantFiled: September 28, 2021Date of Patent: August 22, 2023Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Michimoto Kobayashi, Mitsuaki Sanada, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Publication number: 20220120752Abstract: The present invention provides a method for detecting biliary tract cancer by measuring the amounts of APOA2 protein variants in a test sample with anti-APOA2 antibodies, the anti-APOA2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.Type: ApplicationFiled: December 28, 2021Publication date: April 21, 2022Applicants: Toray Industries, Inc., NATIONAL CANCER CENTERInventors: Mitsuaki Sanada, Michimoto Kobayashi, Aiko Takayama, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Patent number: 11231423Abstract: The present invention provides a method for detecting biliary tract cancer by measuring the amounts of APOA2 protein variants in a test sample with anti-APOA2 antibodies, the anti-APOA2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.Type: GrantFiled: January 25, 2016Date of Patent: January 25, 2022Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Mitsuaki Sanada, Michimoto Kobayashi, Aiko Takayama, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Publication number: 20220011322Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.Type: ApplicationFiled: September 28, 2021Publication date: January 13, 2022Applicants: Toray Industries, Inc., NATIONAL CANCER CENTERInventors: Michimoto Kobayashi, Mitsuaki Sanada, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Patent number: 11162956Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.Type: GrantFiled: March 1, 2016Date of Patent: November 2, 2021Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Michimoto Kobayashi, Mitsuaki Sanada, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Publication number: 20180031574Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.Type: ApplicationFiled: March 1, 2016Publication date: February 1, 2018Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Michimoto Kobayashi, Mitsuaki Sanada, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Publication number: 20180017564Abstract: The present invention provides a method for detecting biliary tract cancer by measuring the amounts of APOA2 protein variants in a test sample with anti-APOA2 antibodies, the anti-APOA2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.Type: ApplicationFiled: January 25, 2016Publication date: January 18, 2018Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Mitsuaki Sanada, Michimoto Kobayashi, Aiko Takayama, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Patent number: 9682961Abstract: The present invention provides a quinazoline derivative represented by the following formula (I): wherein R1 and R2 represent a hydrogen atom, a halogen atom, or a lower alkyl group optionally having a substituent; Z represents a cycloalkyl group having a substituent or a cycloalkenyl group having a substituent; and Q represents a bicyclic heteroaryl group optionally having a substituent, or a pharmaceutically acceptable salt thereof. Since the compound has an inhibitory effect on the Wnt/?-catenin signaling pathway and exhibits an antitumor effect, it is useful as a medicine.Type: GrantFiled: December 5, 2014Date of Patent: June 20, 2017Assignees: CARNA BIOSCIENCES, INC., NATIONAL CANCER CENTERInventors: Hideki Moriyama, Masaaki Sawa, Yuko Uno, Shigeki Kashimoto, Tesshi Yamada
-
Patent number: 9644026Abstract: An antibody against mutant ?-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of ?-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region.Type: GrantFiled: September 9, 2011Date of Patent: May 9, 2017Assignees: TRANS GENIC INC., NATIONAL CANCER CENTERInventors: Shingo Shinagawa, Kazunari Ito, Yoshimi Tokashiki, Tomoaki Miyamoto, Kazufumi Honda, Tesshi Yamada
-
Publication number: 20160264555Abstract: The present invention provides a quinazoline derivative represented by the following formula (I): wherein R1 and R2 represent a hydrogen atom, a halogen atom, or a lower alkyl group optionally having a substituent; Z represents a cycloalkyl group having a substituent or a cycloalkenyl group having a substituent; and Q represents a bicyclic heteroaryl group optionally having a substituent, or a pharmaceutically acceptable salt thereof. Since the compound has an inhibitory effect on the Wnt/?-catenin signaling pathway and exhibits an antitumor effect, it is useful as a medicine.Type: ApplicationFiled: December 5, 2014Publication date: September 15, 2016Applicants: NATIONAL CANCER CENTER, CARNA BIOSCIENCES, INC.Inventors: Hideki MORIYAMA, Masaaki SAWA, Yuko UNO, Shigeki KASHIMOTO, Tesshi YAMADA
-
Publication number: 20160245815Abstract: It is intended to provide a method for detecting a pancreatic tumor (pancreatic cancer or benign pancreatic tumor) with low invasiveness to a test subject and with high detection sensitivity and accuracy. The present invention provides a method for detecting a pancreatic tumor by measuring the amounts of APOA2 protein variants in a sample of a test subject using anti-APOA2 antibodies, anti-APOA2 antibodies for use in the method, and a kit for the detection of a pancreatic tumor, comprising the antibodies.Type: ApplicationFiled: September 30, 2014Publication date: August 25, 2016Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Mitsuaki SANADA, Michimoto KOBAYASHI, Aiko TAKAYAMA, Yoshiyuki SASAJIMA, Giman JUNG, Tesshi YAMADA, Kazufumi HONDA
-
Patent number: 9102637Abstract: The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R1, R2, R3 and Q are as defined in the specification), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 22, 2013Date of Patent: August 11, 2015Assignees: CARNA BIOSCIENCES, INC., NATIONAL CANCER CENTERInventors: Masaaki Sawa, Hideki Moriyama, Tesshi Yamada, Miki Shitashige, Yusuke Kawase, Yuko Uno
-
Publication number: 20150133656Abstract: The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R1, R2, R3 and Q are as defined in the specification), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 22, 2013Publication date: May 14, 2015Applicants: CARNA BIOSCIENCES INC., NATIONAL CANCER CENTERInventors: Masaaki Sawa, Hideki Moriyama, Tesshi Yamada, Miki Shitashige, Yusuke Kawase, Yuko Uno
-
Patent number: 8883972Abstract: The present invention provides an antibody, which reacts with a FGA or FGA partial peptide in which a part of prolines in the molecule thereof are hydroxylated, and which does not react with an unmodified FGA or FGA partial peptide.Type: GrantFiled: February 12, 2009Date of Patent: November 11, 2014Assignees: Transgenic Inc., President, National Cancer CenterInventors: Hiroshi Nose, Tomoyo Hashiguchi, Masaya Ono, Tesshi Yamada, Setsuo Hirohashi
-
Publication number: 20140248261Abstract: An antibody against mutant ?-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of ?-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region.Type: ApplicationFiled: September 9, 2011Publication date: September 4, 2014Applicants: NATIONAL CANCER CENTER, TRANS GENIC INC.Inventors: Shingo Shinagawa, Kazunari Ito, Yoshimi Tokashiki, Tomoaki Miyamoto, Kazufumi Honda, Tesshi Yamada
-
Publication number: 20130317218Abstract: The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R1, R2, R3 and Q are as defined in the specification), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 24, 2012Publication date: November 28, 2013Inventors: Masaaki Sawa, Hideki Moriyama, Tesshi Yamada, Miki Shitashige, Yusuke Kawase, Yuko Uno
-
Publication number: 20130137592Abstract: An object of the present invention is to provide biomarkers for predicting response to chemoradiotherapy for cancer and predicting prognosis of a patient with cancer, as well as methods of measuring such biomarkers. The response to chemoradiotherapy for cancer in a vertebrate animal can be predicted by measuring concentrations of a soluble interleukin-6 receptor, MIP-1?, and an activated plasminogen activator inhibitor in the blood obtained from that individual with cancer before treatment with chemoradiotherapy, and prognosis of the same vertebrate animal can be determined by measuring a concentration of soluble interleukin-6 receptor.Type: ApplicationFiled: March 31, 2011Publication date: May 30, 2013Applicant: NATIONAL CANCER CENTERInventors: Kazufumi Honda, Tesshi Yamada, Yosuke Makuuchi, Yoshiaki Osaka, Setsuo Hirohashi
-
Publication number: 20130052207Abstract: A method of detecting a poor-prognosis stage I lung adenocarcinoma in a mammal, comprising a step of measuring the copy number of ACTN4 gene in the cells of the stage I lung adenocarcinoma tissue obtained from the mammal, wherein, when the copy number of the gene exceeds 4, the stage I lung adenocarcinoma in the mammal is predicted to be a poor-prognosis stage I lung adenocarcinoma.Type: ApplicationFiled: March 29, 2011Publication date: February 28, 2013Applicant: JAPAN HEALTH SCIENCES FOUNDATIONInventors: Kazufumi Honda, Tesshi Yamada, Rintaro Noro, Setsuo Hirohashi
-
Patent number: 8323943Abstract: The screening method for an anticancer drug comprises selecting a compound which blocks the kinase activity of TNIK, or blocks the combination of TNIK with ?-catenin/TC4 transcription complex.Type: GrantFiled: August 13, 2008Date of Patent: December 4, 2012Assignee: National Cancer CenterInventors: Tesshi Yamada, Miki Shitashige, Setsuo Hirohashi
-
Publication number: 20120058204Abstract: The present invention relates to a method of identifying an expression level of cystathionine gamma lyase (CTH) in a sample from a subject. The present invention further discloses a method of diagnosing a subject with cancer having risk of resistance to a platinum-based drug. The present invention also discloses a method for improving efficacy of a platinum-based drug in a subject suffering a cancer.Type: ApplicationFiled: September 7, 2011Publication date: March 8, 2012Applicants: NATIONAL CANCER CENTER RESEARCH INSTITUTE, ABNOVA CORPORATIONInventors: Tesshi Yamada, Kazufumi Honda, Wilber Huang